Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

John P. Sfakianos, MD

Advertisement

Articles by John P. Sfakianos, MD

John P. Sfakianos, MD

Dr Sfakianos on Addressing Unmet Needs With Intravesical Mitomycin in Recurrent, Low-Grade, Intermediate-Risk NMIBC

ByJohn P. Sfakianos, MD
September 5th 2025

John P. Sfakianos, MD, discusses the rationale for evaluating mitomycin intravesical solution in recurrent, low-grade, intermediate-risk NMIBC.

Dr. Sfakianos on Importance of Restaging Transurethral Resection of Bladder Tumors

ByJohn P. Sfakianos, MD
May 12th 2020

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

Advertisement

Latest Updated Articles

  • Dr. Sfakianos on Importance of Restaging Transurethral Resection of Bladder Tumors
    Dr. Sfakianos on Importance of Restaging Transurethral Resection of Bladder Tumors

    May 12th 2020



Advertisement
Advertisement

Trending on OncLive

1

Targeted Therapies, ADCs, and Oral SERD Combos Expand Treatment Possibilities Across Breast Cancer Settings

2

Generic Ga-68 PSMA-11 Radiodiagnostic Nets FDA Approval in Prostate Cancer

3

Sonrotoclax Plus Zanubrutinib Yields High Undetectable MRD Rates in Treatment-Naive CLL/SLL

4

Panitumumab-Based Regimens Yield High Response Rates in Heavily Pretreated RMC

5

ASCO 2026 Ushers In a New Era for Pancreatic Cancer, Expands Targeted Therapy Options Across the GI Spectrum

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us